Science and technical ventures

The gap ventures fall into

The pattern is familiar to anyone who has commercialised research. The result is real: peer-reviewed, demonstrated, admired. The demonstrator works, in the hands of the people who built it, on the data it was built with. And then the venture reaches the part the lab never prepares you for: a first customer who needs it to work unattended, an investor who needs evidence the prototype cannot produce, a deployment into an operation with rules the research never met.

What is missing is rarely intelligence or effort. It is a product boundary: a deliberate decision about what the product is, what stays research, and what the first customers are actually buying. Everything else, the engineering, the evidence, the pricing of the roadmap, hangs off that decision, and most technical ventures make it by accident. Made deliberately, it becomes the moment the venture starts compounding.

What we help with

Product boundary definition

Deciding what the product is and is not: which capabilities are promises, which are experiments, and what the minimum dependable offering looks like. This is diagnosis work, and it is where most ventures should start.

Evidence building

Identifying and building the technical, commercial and operational evidence the next milestone actually requires: the benchmark that convinces a customer, the reliability data that convinces a regulator, the unit economics that convinces an investor.

Productisation and engineering

Turning the demonstrator into a dependable, deployable, supportable capability: production engineering, evaluation, packaging, documentation and the unglamorous corridor between prototype and product.

Deployment into real operations

Taking the product into the complex, regulated environments where its value lives, which is our home territory: governance, integration with incumbent systems, and adoption by sceptical professional users.

Scale-up leadership

Fractional technology and product leadership through the awkward stage between founder-led and fully staffed, including helping define and land the permanent hires that end the arrangement.

IP and partnership boundaries

Keeping ownership, licensing and collaboration lines clear while the venture takes shape, so the value being built stays where it belongs. We work alongside your legal advisers here, not instead of them.

How we respect the science

Commercialisation has a deserved reputation for flattening the science it touches: rounding capabilities up, rounding caveats down, and leaving the researchers to watch their work oversold. We work the other way. The science leads; productisation sharpens its value rather than overwriting it. Claims run behind evidence. Caveats survive into the marketing. A product built that way earns slower, sturdier trust, which is the only kind that survives contact with a serious customer's technical diligence, the same test we help investors apply.

Who this is for

Founders commercialising research, universities and commercialisation teams shaping spinouts, technical teams inside established organisations productising an internal capability, and investors backing any of the above. If the venture's value rests on science or engineering that has to become a dependable product in a demanding environment, the fit is probably strong; the way to find out is to tell us about the next milestone.